Pacritinib’s Lack of Myelosuppression May Be Due to Lack of JAK1, IRAK1 Inhibition
Profile of pacritinib suggests potential role in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Profile of pacritinib suggests potential role in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Investigators validated the German High-Grade Non-Hodgkin Lymphoma Study Group’s new prognostic model for aggressive B-cell lymphoma.
Addition of radiotherapy should be reserved for the minority of patients with non-bulky limited-stage diffuse large B cell lymphoma (DLBCL).
Pomalidomide, bortezomib, and dexamethasone is a highly effective combination in multiple myeloma refractory to lenalidomide.
CTL019 cells cause strong, durable responses in pediatric patients with relapsed, refractory acute lymphocytic leukemia (ALL).
Blinatumomab resulted in complete minimal residual disease (MRD) in 78% of patients with acute lymphocytic leukemia (ALL).
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Nivolumab-mediated programmed cell death-1 (PD-1) blockade produced responses in classical Hodgkin lymphoma (cHL).
Pacritinib suppresses leukemic outgrowth from stroma-adherent cells in FLT3-ITD-driven acute myeloid leukemia (AML).
Induction with the lenalidomide, doxorubicin, dexamethasone (RAD) triplet is effective in newly diagnosed multiple myeloma.
Please login or register first to view this content.